The appeal of mEVs begins with their membrane. Cholesterol, sphingomyelin and ceramides help create a relatively robust lipid bilayer that shields internal cargo from environmental damage. Studies summarized in the review indicate that milk vesicles can remain intact under simulated gastrointestinal conditions and protect RNA from digestive enzymes such as ribonucleases. After oral administration, vesicles may interact with intestinal epithelial cells through endocytosis, membrane fusion or receptor-mediated uptake, allowing their contents to enter recipient cells. Some experimental work also suggests that milk vesicles or their cargo can reach tissues beyond the gut, including the brain. This possibility is particularly important because the blood-brain barrier restricts many therapeutic molecules. However, crossing that barrier in animal or cellular models does not establish effective delivery in people. Biodistribution depends on vesicle size, surface proteins, cargo, dose, species of origin, processing conditions and administration route. The review therefore treats gastrointestinal stability and barrier transport as promising properties, not guarantees of therapeutic performance.

Milk vesicles are not a single uniform material. The broader extracellular-vesicle population includes exosomes, microvesicles and apoptotic bodies, which differ in size and how they form. Exosomes develop inside multivesicular bodies when endosomal membranes bud inward to create intraluminal vesicles; multivesicular bodies can then fuse with the plasma membrane and release them. Microvesicles form by outward budding of the cell surface, involving calcium-dependent cytoskeletal changes and redistribution of membrane lipids. In milk, the vesicle population is shaped by the animal species, lactation stage, maternal physiology, diet and health status. Bovine, human, goat, camel, porcine and equine milk can therefore contain different mixtures of proteins and regulatory RNAs. Commonly measured surface or intracellular markers include CD9, CD63, CD81, TSG101 and Alix, but marker detection alone does not define purity or biological function. The review calls for multi-method characterization that combines particle sizing, microscopy, protein analysis, RNA profiling and functional testing.

Obtaining clean vesicles from milk is technically difficult because milk is a complex mixture containing casein micelles, soluble proteins, fat globules and other particles with overlapping physical properties. Differential ultracentrifugation remains widely used, separating material according to size and density, but it can be slow and may promote aggregation or structural damage. Ultrafiltration and polyethylene-glycol precipitation are easier to scale, yet they can recover non-vesicular contaminants. Size-exclusion chromatography separates particles by hydrodynamic size and is often combined with other methods to improve purity. Immunoaffinity capture can select vesicles carrying particular surface markers, although it may reduce recovery and exclude biologically relevant subpopulations. Emerging microfluidic and immunomagnetic systems could enable automated processing of small volumes, while tangential-flow filtration combined with chromatography offers a possible route toward larger-scale production. Across all approaches, researchers need consistent measurements of particle number, size distribution, morphology, membrane integrity, cargo and contaminating milk proteins.

As delivery systems, mEVs could carry molecules that otherwise degrade quickly or dissolve poorly. The review describes experimental loading with polyphenols such as curcumin, resveratrol, quercetin and epigallocatechin gallate, as well as chemotherapeutic compounds including paclitaxel and doxorubicin. Encapsulation may improve aqueous dispersal, protect cargo during digestion and increase contact with intestinal tissues. Vesicles have also been investigated for transporting small interfering RNA, microRNA, messenger RNA, peptides and proteins. In principle, this creates a dual-purpose platform: the vesicle’s native cargo may influence recipient cells, while an added therapeutic molecule supplies a designed activity. Surface engineering could further attach targeting ligands or alter tissue distribution. Yet loading is not straightforward. Passive incubation, membrane permeabilization and other approaches can produce different encapsulation efficiencies and may damage the vesicle. A useful product would require reproducible cargo content, predictable release kinetics and evidence that the loaded molecule reaches the intended tissue at a clinically meaningful dose.

The biological effects reported across models are broad but uneven. In intestinal systems, milk vesicles have been associated with stronger tight junctions, including proteins such as ZO-1, occludin and claudin-1, and with reduced inflammatory signaling. MicroRNAs including miR-148a, miR-21, miR-30a and miR-146b may influence pathways involving NF-κB, Toll-like receptors, DNA methylation and the NLRP3 inflammasome. In cell and animal studies, these mechanisms have been linked to lower inflammatory cytokines, improved barrier function and protection from oxidative stress. Other experiments report effects on macrophage polarization, with some mEV preparations encouraging an anti-inflammatory state. Researchers have also examined bone, liver, heart, lung and pancreatic applications. Milk vesicles have been tested in models of colitis, metabolic dysfunction, fibrosis, osteoporosis, vascular injury and pulmonary inflammation. These findings suggest multiple possible mechanisms, including direct cargo transfer, modulation of gut microbiota and communication along the gut-liver or gut-heart axes, but they do not demonstrate that drinking milk or consuming an unstandardized vesicle preparation treats disease.

Several findings illustrate why careful interpretation is essential. In mice, orally administered milk vesicles have been reported to cross the blood-brain barrier, increase hippocampal dendritic complexity and improve selected cognitive or motor outcomes. Other studies have found changes in microglial DNA-methylation machinery or neuronal survival in cellular models. At the same time, neurological results vary with dose, species, metabolic context and experimental design. A separate line of research has raised hypotheses about interactions between milk exosomes and excessive galactose exposure, while other work found that aging had stronger effects on rat brain lipid profiles and cognition than an extracellular-vesicle-rich supplement. Lung studies likewise include contrasting observations: some mEV preparations protect epithelial barriers or deliver anti-fibrotic compounds, whereas bovine vesicles increased inflammatory macrophage polarization in mice exposed to agricultural dust. In cancer research, vesicles have delivered drugs and gene regulators to tumour models, but one study reported that oral bovine milk vesicles slowed primary-tumour growth while accelerating metastasis. Such results make clear that mEVs are biologically active, context-dependent materials rather than universally beneficial particles.

Translation will depend on proving safety and manufacturing consistency as much as on demonstrating biological activity. Milk origin does not automatically eliminate risk. Preparations can retain caseins, beta-lactoglobulin and other proteins that may trigger reactions in people with milk allergy. Repeated exposure also requires assessment of immune activation, liver and kidney function, oxidative stress, tissue distribution and delayed toxicity. Thermal processing can reduce vesicle yield or disrupt structure, complicating the relationship between fresh milk, pasteurized products and purified formulations. Regulators will also need to determine whether a given product is a food, supplement, biologic, nanomedicine or combination product, since each category carries different requirements. The review points toward standardized isolation protocols, validated vesicle markers, sensitive contaminant testing, single-vesicle and multi-omic analysis, stable storage methods and Good Manufacturing Practice production. Human pharmacokinetic and clinical studies will be decisive. For now, milk-derived extracellular vesicles represent a promising natural nanocarrier platform whose future rests on converting intriguing laboratory observations into reproducible, well-controlled and demonstrably safe interventions.

A further advantage of mEVs is that their value may extend beyond their role as passive containers. Their membranes carry naturally occurring adhesion molecules, tetraspanins and transport-related components that can influence how vesicles are recognized, internalized and distributed. This biological interface distinguishes them from liposomes and polymeric nanoparticles, whose composition can be tuned with considerable precision but generally requires deliberate surface engineering to achieve comparable interactions with cells. The contrast is not absolute: synthetic systems offer stronger control over particle uniformity, drug loading and release kinetics, while mEVs offer a more physiologically integrated membrane and a potentially favorable safety profile. Hybrid designs that combine EV membranes with synthetic cores therefore represent one strategy for balancing biological compatibility with manufacturing control.

The native cargo also complicates how mEV products should be designed and evaluated. A preparation intended to deliver an added drug or RNA may simultaneously contain endogenous proteins, lipids, microRNAs and metabolites capable of altering immune or metabolic responses. Those constituents could contribute to efficacy, but they could also vary with animal species, lactation conditions, feed, health status and processing history. Consequently, measuring total particle concentration is insufficient for comparing products. Functional potency assays will need to establish whether a defined preparation produces a reproducible cellular response, while molecular profiling can help identify which cargo components are retained, enriched or lost during isolation and loading. This is especially important when the desired activity depends on cooperation between the vesicle membrane and its internal contents rather than on a single therapeutic molecule.

Manufacturing scale is promising but should not be confused with readiness for routine clinical use. Milk provides a comparatively accessible starting material, and the review describes ultracentrifugation, size-exclusion chromatography and precipitation methods as established approaches, with tangential-flow and related technologies offering routes toward process intensification. At larger scale, however, purification must preserve membrane integrity while removing abundant non-vesicular milk constituents and maintaining consistent particle and cargo characteristics. The field has reached early translational milestones, including a reported first clinical trial involving mEV-based formulations for RNA therapeutics and anticancer agents, but such studies are only an initial test of feasibility. Results from carefully controlled human investigations will need to define dose, absorption, biodistribution, immune effects and clinically meaningful benefit before the farm-to-pharmacy concept can support approved interventions.

Subject of Research: Milk-derived extracellular vesicles as nutritional and therapeutic nanocarriers

Article Title: Milk-derived extracellular vesicles: nutritional significance, nano-delivery potential, and emerging therapeutic applications – an updated review

Article References: Wang, S., Shaukat, A., Al-Rasheed, M., Tareen, A. M., Arain, M. A., & Luo, C. (2026). Milk-derived extracellular vesicles: nutritional significance, nano-delivery potential, and emerging therapeutic applications – an updated review. Food Science of Animal Resources, 46(1), Article 96. https://doi.org/10.1007/s44463-026-00104-6

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00104-6

Keywords: extracellular vesicles, milk nanocarriers, nutraceutical delivery, drug delivery, microRNAs, precision medicine, gut health, nanomedicine, Milk-derived, extracellular, vesicles, nutritional

Copper, long acknowledged for its powerful antimicrobial properties, has faced challenges when it comes to its application in clinical settings. High concentrations of copper can be cytotoxic, leading to potential harm to cells. The introduction of CiMs enables a controlled release of copper ions, encapsulated within microvesicles. These microvesicles are small membrane-bound vesicles that transport bioactive molecules, facilitating intercellular communication. By encapsulating copper within these vesicles, the risk of toxicity is significantly reduced while still delivering effective therapeutic benefits.

CiMs are remarkable in their ability to promote tissue regeneration, enhance cellular growth, and improve blood vessel formation, all of which are crucial for effective healing in dental applications. The multifunctional nature of these microvesicles makes them a key player in not only addressing dental diseases but also in broader medical applications such as wound healing and regenerative therapies. This exploration into the utility of CiMs could lead to a transformative shift in the approach to oral health, providing an alternative to traditional methods that often involve more invasive procedures and extended recovery times.

Given Chile’s status as the world’s largest producer of copper, this cutting-edge technology positions the nation at the forefront of dental innovation. Prof. Dr. Haidar and his team at BioMAT’X are engaged in ongoing research and development efforts to refine the synthesis and characterization of these microvesicles. This work is pivotal for optimizing their performance in various in vitro and in vivo models, ultimately paving the way for new dental devices and biomaterials that enhance patient care.

The implications of CiMs extend far beyond dentistry. Researchers envision their application in various medical fields, particularly in regenerative therapies and advanced drug delivery systems. The versatility of microvesicles to serve as biocompatible carriers opens a new realm of possibilities in therapeutic contexts. By ensuring a controlled and sustained release of encapsulated elements, CiMs could lead to improved treatment protocols for chronic conditions where ongoing intervention is necessary.

As CiMs continue to evolve as an innovative solution in healthcare, the avenue for clinical testing and regulatory approval must be navigated. Agencies like the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) require rigorous evaluations to ascertain the safety and efficacy of new medical products before they can be adopted into standard practice. Demonstrating the long-term benefits of CiMs and their cost-effectiveness will be essential in facilitating successful market entry.

Despite the challenges that lie ahead, the outlook for copper-incorporated microvesicles is heartening. Ongoing projects at BioMAT’X I+D+I LABs are dedicated to unlocking new applications and harnessing the therapeutic potential of these microvesicles across various medical disciplines. The ongoing research not only holds promise for enhanced dental care but aims to address diverse medical challenges, positioning CiMs as a versatile solution.

In conclusion, the introduction of copper-incorporated microvesicles heralds a new era in biofunctional medicine, fostering hope for improved health outcomes through innovative technology. As the scientific community pays closer attention to these advancements, collaborations between researchers, regulatory agencies, and healthcare providers will be crucial. Future updates are anticipated as this technology continues to develop and mature, potentially reshaping the landscape of dental treatments and offering transformative benefits for oral health.

The excitement surrounding CiMs serves as a reminder of the unlimited potential of scientific innovations in healthcare. As more researchers explore the capabilities of materials like copper within therapeutic contexts, the horizons of medicine expand, leading to better patient outcomes and enhanced quality of life.

This research signifies a major leap in dental innovation, appealing not only to dental professionals but also to anyone interested in the evolving sphere of biomedical technology. The diligent work undertaken by Prof. Dr. Haidar and his team reiterates the importance of innovative thinking and scientific inquiry in addressing pressing health concerns confronting society today.

Copper-incorporated microvesicles represent the future of dental care—dynamic, proactive, and seamlessly integrating advanced materials science with practical medical applications. For anyone focused on the peaks of scientific discovery and its implications for health, the journey of CiMs is one to closely follow as it unfolds.

Subject of Research: Not applicable
Article Title: Copper-incorporated microvesicles: a new frontier in dentistry and oral surgery?
News Publication Date: 27-Feb-2025
Web References: http://dx.doi.org/10.55092/bm20250004
References: Not provided
Image Credits: ZS HAiDAR/BioMAT’X I+D+I LABs, Santiago de Chile.
Keywords: Copper, Microvesicles, Dental care, Tissue regeneration, Biomedical technology.